Autologous bone marrow transplantation in acute myelogenous leukemia

In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination

Roberto M. Lemoli, Christina Gasparetto, David A. Scheinberg, Malcom A S Moore, Bayard D. Clarkson, Subhash C. Gulati

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We report the results of a preclinical study comparing four different purging protocols using a promyelocytic human cell line HL-60 and myeloid leukemic progenitor cells (colonyforming unit-leukemic [CFU-L]) from acute myelogenous leukemia (AML) patients assayed in semisolid culture. We studied the antileukemic effect of (1) Single-cycle complement-mediated lysis by two different monoclonal antibodies (MoAbs) (M195 [CD33] and F23 [CD13] 40 μg/mL), reactive with distinct antigens found on early myeloid cells and monocytes, used alone and in combinations; (2) 4-Hydroperoxycyclophosphamide (4-HC) (80 μmol/L or 100 μmol/L) alone; or (3) combined with VP-16 (5 μg/mL) and (4) a cocktail of 1 through 3 as above (combined immunochemotherapy). More than 4 logs of HL-60 tumor cell elimination were observed after 1 hour of incubation with both MoAbs plus 4-HC + VP-16 while the single treatment (immunotherapy or chemotherapy) provided 1.5 and 3.5 logs of colonyforming inhibition, respectively. When the same protocols were tested on cryopreserved leukemic cells from eight patients with AML, we observed a mean value of CFU-L inhibition of 92.3% ± 2.5% SD, 95.5% ± 1.4% SD, and 99% ± 0.8% SD after MoAbs and complement lysis, 4-HC, and 4-HC + VP-16 treatment, respectively. The combined treatment of MoAbs and 4-HC + VP-16 produced more than 3-log reduction of CFU-L colony formation. By comparison, the mean recovery of committed normal bone marrow progenitors after incubation with MoAbs and complement was 12% for CFU-granulocyte-macrophage (CFU-GM), 22.9% for burstforming unit erythroid (BFU-E), and the recovery following 4-HC + VP-16 treatment was 4.4% for CFU-GM and 5.6% BFU-E. In subsequent experiments, highly purified CD34+ blast cells, enriched by positive selection, and stimulated in liquid culture by cytokines (interleukin-1 [IL-1], IL-3, and combination of both) or MO-conditioned medium (MoCM), demonstrated that immunochemotherapy spares hematopoietic colony-forming cells earlier than day 14 CFU-GM, in vitro.

Original languageEnglish
Pages (from-to)1829-1836
Number of pages8
JournalBlood
Volume77
Issue number8
Publication statusPublished - Apr 15 1991

Fingerprint

perfosfamide
Autologous Transplantation
Drug Combinations
Bone Marrow Transplantation
Acute Myeloid Leukemia
Etoposide
Bone
Monoclonal Antibodies
Macrophages
Granulocytes
Pharmaceutical Preparations
Therapeutics
Cells
Complement C4
Myeloid Progenitor Cells
Purging
Recovery
Erythroid Precursor Cells
Chemotherapy
Interleukin-3

ASJC Scopus subject areas

  • Hematology

Cite this

Lemoli, R. M., Gasparetto, C., Scheinberg, D. A., Moore, M. A. S., Clarkson, B. D., & Gulati, S. C. (1991). Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood, 77(8), 1829-1836.

Autologous bone marrow transplantation in acute myelogenous leukemia : In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. / Lemoli, Roberto M.; Gasparetto, Christina; Scheinberg, David A.; Moore, Malcom A S; Clarkson, Bayard D.; Gulati, Subhash C.

In: Blood, Vol. 77, No. 8, 15.04.1991, p. 1829-1836.

Research output: Contribution to journalArticle

Lemoli, Roberto M. ; Gasparetto, Christina ; Scheinberg, David A. ; Moore, Malcom A S ; Clarkson, Bayard D. ; Gulati, Subhash C. / Autologous bone marrow transplantation in acute myelogenous leukemia : In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. In: Blood. 1991 ; Vol. 77, No. 8. pp. 1829-1836.
@article{f26ea7143d6745b28a73e12dd77ef124,
title = "Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination",
abstract = "We report the results of a preclinical study comparing four different purging protocols using a promyelocytic human cell line HL-60 and myeloid leukemic progenitor cells (colonyforming unit-leukemic [CFU-L]) from acute myelogenous leukemia (AML) patients assayed in semisolid culture. We studied the antileukemic effect of (1) Single-cycle complement-mediated lysis by two different monoclonal antibodies (MoAbs) (M195 [CD33] and F23 [CD13] 40 μg/mL), reactive with distinct antigens found on early myeloid cells and monocytes, used alone and in combinations; (2) 4-Hydroperoxycyclophosphamide (4-HC) (80 μmol/L or 100 μmol/L) alone; or (3) combined with VP-16 (5 μg/mL) and (4) a cocktail of 1 through 3 as above (combined immunochemotherapy). More than 4 logs of HL-60 tumor cell elimination were observed after 1 hour of incubation with both MoAbs plus 4-HC + VP-16 while the single treatment (immunotherapy or chemotherapy) provided 1.5 and 3.5 logs of colonyforming inhibition, respectively. When the same protocols were tested on cryopreserved leukemic cells from eight patients with AML, we observed a mean value of CFU-L inhibition of 92.3{\%} ± 2.5{\%} SD, 95.5{\%} ± 1.4{\%} SD, and 99{\%} ± 0.8{\%} SD after MoAbs and complement lysis, 4-HC, and 4-HC + VP-16 treatment, respectively. The combined treatment of MoAbs and 4-HC + VP-16 produced more than 3-log reduction of CFU-L colony formation. By comparison, the mean recovery of committed normal bone marrow progenitors after incubation with MoAbs and complement was 12{\%} for CFU-granulocyte-macrophage (CFU-GM), 22.9{\%} for burstforming unit erythroid (BFU-E), and the recovery following 4-HC + VP-16 treatment was 4.4{\%} for CFU-GM and 5.6{\%} BFU-E. In subsequent experiments, highly purified CD34+ blast cells, enriched by positive selection, and stimulated in liquid culture by cytokines (interleukin-1 [IL-1], IL-3, and combination of both) or MO-conditioned medium (MoCM), demonstrated that immunochemotherapy spares hematopoietic colony-forming cells earlier than day 14 CFU-GM, in vitro.",
author = "Lemoli, {Roberto M.} and Christina Gasparetto and Scheinberg, {David A.} and Moore, {Malcom A S} and Clarkson, {Bayard D.} and Gulati, {Subhash C.}",
year = "1991",
month = "4",
day = "15",
language = "English",
volume = "77",
pages = "1829--1836",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Autologous bone marrow transplantation in acute myelogenous leukemia

T2 - In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination

AU - Lemoli, Roberto M.

AU - Gasparetto, Christina

AU - Scheinberg, David A.

AU - Moore, Malcom A S

AU - Clarkson, Bayard D.

AU - Gulati, Subhash C.

PY - 1991/4/15

Y1 - 1991/4/15

N2 - We report the results of a preclinical study comparing four different purging protocols using a promyelocytic human cell line HL-60 and myeloid leukemic progenitor cells (colonyforming unit-leukemic [CFU-L]) from acute myelogenous leukemia (AML) patients assayed in semisolid culture. We studied the antileukemic effect of (1) Single-cycle complement-mediated lysis by two different monoclonal antibodies (MoAbs) (M195 [CD33] and F23 [CD13] 40 μg/mL), reactive with distinct antigens found on early myeloid cells and monocytes, used alone and in combinations; (2) 4-Hydroperoxycyclophosphamide (4-HC) (80 μmol/L or 100 μmol/L) alone; or (3) combined with VP-16 (5 μg/mL) and (4) a cocktail of 1 through 3 as above (combined immunochemotherapy). More than 4 logs of HL-60 tumor cell elimination were observed after 1 hour of incubation with both MoAbs plus 4-HC + VP-16 while the single treatment (immunotherapy or chemotherapy) provided 1.5 and 3.5 logs of colonyforming inhibition, respectively. When the same protocols were tested on cryopreserved leukemic cells from eight patients with AML, we observed a mean value of CFU-L inhibition of 92.3% ± 2.5% SD, 95.5% ± 1.4% SD, and 99% ± 0.8% SD after MoAbs and complement lysis, 4-HC, and 4-HC + VP-16 treatment, respectively. The combined treatment of MoAbs and 4-HC + VP-16 produced more than 3-log reduction of CFU-L colony formation. By comparison, the mean recovery of committed normal bone marrow progenitors after incubation with MoAbs and complement was 12% for CFU-granulocyte-macrophage (CFU-GM), 22.9% for burstforming unit erythroid (BFU-E), and the recovery following 4-HC + VP-16 treatment was 4.4% for CFU-GM and 5.6% BFU-E. In subsequent experiments, highly purified CD34+ blast cells, enriched by positive selection, and stimulated in liquid culture by cytokines (interleukin-1 [IL-1], IL-3, and combination of both) or MO-conditioned medium (MoCM), demonstrated that immunochemotherapy spares hematopoietic colony-forming cells earlier than day 14 CFU-GM, in vitro.

AB - We report the results of a preclinical study comparing four different purging protocols using a promyelocytic human cell line HL-60 and myeloid leukemic progenitor cells (colonyforming unit-leukemic [CFU-L]) from acute myelogenous leukemia (AML) patients assayed in semisolid culture. We studied the antileukemic effect of (1) Single-cycle complement-mediated lysis by two different monoclonal antibodies (MoAbs) (M195 [CD33] and F23 [CD13] 40 μg/mL), reactive with distinct antigens found on early myeloid cells and monocytes, used alone and in combinations; (2) 4-Hydroperoxycyclophosphamide (4-HC) (80 μmol/L or 100 μmol/L) alone; or (3) combined with VP-16 (5 μg/mL) and (4) a cocktail of 1 through 3 as above (combined immunochemotherapy). More than 4 logs of HL-60 tumor cell elimination were observed after 1 hour of incubation with both MoAbs plus 4-HC + VP-16 while the single treatment (immunotherapy or chemotherapy) provided 1.5 and 3.5 logs of colonyforming inhibition, respectively. When the same protocols were tested on cryopreserved leukemic cells from eight patients with AML, we observed a mean value of CFU-L inhibition of 92.3% ± 2.5% SD, 95.5% ± 1.4% SD, and 99% ± 0.8% SD after MoAbs and complement lysis, 4-HC, and 4-HC + VP-16 treatment, respectively. The combined treatment of MoAbs and 4-HC + VP-16 produced more than 3-log reduction of CFU-L colony formation. By comparison, the mean recovery of committed normal bone marrow progenitors after incubation with MoAbs and complement was 12% for CFU-granulocyte-macrophage (CFU-GM), 22.9% for burstforming unit erythroid (BFU-E), and the recovery following 4-HC + VP-16 treatment was 4.4% for CFU-GM and 5.6% BFU-E. In subsequent experiments, highly purified CD34+ blast cells, enriched by positive selection, and stimulated in liquid culture by cytokines (interleukin-1 [IL-1], IL-3, and combination of both) or MO-conditioned medium (MoCM), demonstrated that immunochemotherapy spares hematopoietic colony-forming cells earlier than day 14 CFU-GM, in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0025818594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025818594&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 1829

EP - 1836

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -